page vii

510(K) SUMMARY

OCT 0 4 2002

Date:

February 28, 2002

Company:

Physiometrix, Inc. Five Billerica Park 101 Billerica Avenue N. Billerica, MA 01862

Contact:

Dawn E. Frazer

Vice President

Regulatory Affairs & Quality Assurance

(978) 670-2422 x243 dfrazer@physiometrix.com

Subject Device:

PSA4000 EEG Monitor with Frontal PSI

Classification:

Class II, 21 CFR Part 882.1400, Electroencephalograph

Intended Use:

The PSA4000 is indicated for use in the operating room (OR), intensive care unit (ICU), and clinical research laboratory. It is intended to monitor the state of the brain by real-time data acquisition and processing of EEG signals. The system includes the Patient State Index (PSI™), a proprietary computed EEG variable

that is related to the effect of anesthetic agents.

Photograph:



Description:

The PSA4000 is an EEG monitor designed for use in the OR, ICU, EEG laboratory and for clinical research. It provides the ability to acquire and display real-time EEG waveforms, process the real time EEG data using digital signal

K020671 page 2563

page viii

processing techniques, display the processed EEG data in several different formats, and archive the real-time or processed EEG data for future review.

The PSA4000 consists of three main components, the monitor, the amplifier and the archive media (optional). The device performs automatic self tests upon power up to ensure that the monitor and its components are functioning properly.

Monitor

The monitor provides signal processing and display capabilities for the 4 channels of real-time EEG data acquired from the preamplifier.

The monitor dimensions are 8.5" wide $\times 6.75$ " high $\times 20.75$ " deep. The color display area is 3.75" high $\times 5.2$ " wide. In addition to the display area, the front panel is configured with a number of soft and hard keys to allow for configuration of the display and data acquisition settings.

The processor is a PC-based CPU that processes the EEG data, calculates the processed parameters and displays the real-time EEG data and processed data. Processed parameters include Electromyograph (EMG), Artifact (ART), Suppression Ratio (SR), and the Patient State Index (PSI).

Patient Module

The patient module is an electrically isolated, low noise, high gain, analog to digital signal converter that can process up to 4 channels of real-time data. The preamplifier dimensions are 4.25" wide x 1.75" thick x 5.5" high. The patient module includes a clamp that can be used to secure the unit. The clamp can accommodate a pole of up to 1" in diameter. The preamplifier is connected to the patient and monitor through flexible, shielded cabling.

Archive Media (optional)

The PSA4000 has an optional PCMCIA slot. When a PCMCIA card is detected on start up of the monitor, data will be automatically stored on the PCMCIA Hard Disk Drive.

Predicate Device:

PSA4000 EEG Monitor with PSI (K001069)

Similarities:

The subject device is similar to the predicate device in the following ways:

- a. Both systems are EEG monitors.
- b. Both systems provide a variety of processed parameters.
- Both systems include a proprietary computed EEG variable that is related to the affects of anesthetics.
- d. Both conduct self tests at start up to assure that the device is operating.
- e. Both systems have two main components, a monitor and a preamplifier.

Differences:

The subject device is different from the predicate device in the following way:

a. The subject device is intended for use with the PSArray², which consists of 6 electrodes located on the forehead while the predicate device is intended for

16020671 page Jef]

page ix

use with the PSArray, which consists of 7 electrodes located on the forehead, scalp and ears.

Test Results:

The following tests have been conducted in order to verify and validate the device: software, mechanical and electrical validation testing and EMC testing.

The PSA4000 has been testing in accordance with the following standards.

- UL 2601
- CSA 22.2 No. 601-1
- IEC 601-1
- IEC 601-2-26
- FDA Reviewer Guidance for Premarket Notification Submissions, Section 7, Electromagnetic Compatibility dated November 1993.

The test results are all positive and indicate that the device meets product requirements and satisfies customer needs and expectations.



OCT 0 4 2002

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Dawn E. Frazer
Vice President, Regulatory Affairs
and Quality Assurance
Physiometrix, Inc.
Five Billerica Park
101 Billerica Avenue
N. Billerica, Massachusetts 01862

Re: K020671

Trade/Device Name: PSA4000 EEG Monitor with Frontal PSI

Regulation Number: 882.1400

Regulation Name: Electroencephalograph

Regulatory Class: II Product Code: FYX Dated: October 1, 2002 Received: October 2, 2002

Dear Ms. Frazer:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Applicant:

Prescription Use

(Per 21 CFR 801.109)

INDICATIONS FOR USE STATEMENT

Physiometrix, Inc.

510(k) Number (if known)	Not assigned
Device Name	PSA4000 EEG Monitor with Frontal PSI
Indications For Use	The PSA4000 EEG Monitor with Frontal PSI is indicated for use in the operating room (OR), intensive care unit (ICU), and clinical research laboratory. It is intended to monitor the state of the brain by real-time data acquisition and processing of EEG signals. The system includes the Patient State Index (PSI™), a proprietary computed EEG variable that is related to the effect of anesthetic agents.
(PLEASE DO NOT WRITE BELOW THIS LINE CONTINUE ON ANOTHER PAGE IF NEEDED)	
Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative and Neurological Devices	
	510(k) Number K020671

OR

Over-The-Counter Use _____